Novozymes, Danish biotech giant, today announced the acquisition of microbial research company Organobalance GmbH for an undisclosed amount. Germany-based Organobalance owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology. It specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health.
The term start-up has burst on the political agenda of the Italian government. First with the Minister Corrado Passera, who in the period past at the Ministry for Economic Development was able to approve the decree Development 2.0, now with Premier Enrico Letta, who in the start-ups sees a fundamental tool to solve the tragedy of youth unemployment and who recently promised to “remove barriers and bureaucracy” to set up a business.
In the various sectors of the bioeconomy, there are many start-ups founded in Italy in recent years. One of these is Micro4you, a spin-off of the University of Milan, specialized in the production of micro-organisms for a variety of uses: from the restoration of historical monuments to animal health. In this interview, its CEO, Annalisa Balloi, tells how is a young innovative company and what are the real problems that it faces. Since “for those who – like us – focuses its attention on niche products, the administrative procedures are too complex and expensive”.
Interview by Mario Bonaccorso